This article was originally published in The Gray Sheet
Brightened image through name change to CardioGenesis is foreseen by the transmyocardial revascularization system developer. Announced June 18, the change reflects plans to offer a broader range of products for cardiovascular disease, possibly including delivery systems for growth factor compounds. The new appellation is taken from a March 1999 acquisition by the same name. The firm's stock symbol also changes June 21 to "CGCP." The Sunnyvale, California company simultaneously announces plans to move its headquarters from Silicone Valley to Foothill Ranch, California by August to cut expenses. A PMA supplement for the firm's percutaneous myocardial revascularization system is scheduled for FDA panel review July 9...
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.